HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Tom Decroo Selected Research

Rifampin (Rifampicin)

4/2022Definitive outcomes in patients with rifampicin-resistant tuberculosis treated in Niger from 2012 to 2019: A retrospective cohort study.
4/2022Acquired rifampicin resistance during first TB treatment: magnitude, relative importance, risk factors and keys to control in low-income settings.
1/2022Person-centred care and short oral treatment for rifampicin-resistant tuberculosis improve retention in care in Kandahar, Afghanistan.
1/2022Bedaquiline can act as core drug in a standardised treatment regimen for fluoroquinolone-resistant rifampicin-resistant tuberculosis.
1/2022Pretomanid for tuberculosis: a systematic review.
12/2021Second-line injectable drugs for rifampicin-resistant tuberculosis: better the devil we know?
5/2021Should treatment of low-level rifampicin mono-resistant tuberculosis be different?
2/2021Low Cycle Threshold Value in Xpert MTB/RIF Assay May Herald False Detection of Tuberculosis and Rifampicin Resistance: A Study of Two Cases.
1/2021Case Report: Therapeutic Threshold for Rifampicin-Resistant Tuberculosis in a Patient from Maputo, Mozambique.
1/2021Predictors of Rifampicin-Resistant Tuberculosis Mortality among HIV-Coinfected Patients in Rwanda.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Tom Decroo Research Topics

Disease

23Tuberculosis (Tuberculoses)
04/2022 - 12/2019
7Multidrug-Resistant Tuberculosis (Drug-Resistant Tuberculosis)
04/2022 - 11/2019
3Ototoxicity
01/2021 - 01/2020
2Hearing Loss (Hearing Impairment)
01/2021 - 06/2020
1Reinfection
04/2022
1Opportunistic Infections (Opportunistic Infection)
01/2021
1Communicable Diseases (Infectious Diseases)
11/2019
1Infections
02/2016
1Chronic Disease (Chronic Diseases)
04/2014
1Syphilis
11/2011

Drug/Important Bio-Agent (IBA)

23Rifampin (Rifampicin)FDA LinkGeneric
04/2022 - 11/2019
6FluoroquinolonesIBA
01/2022 - 12/2019
4Isoniazid (Ftivazide)FDA LinkGeneric
04/2022 - 01/2020
4bedaquiline (R207910)IBA
04/2022 - 01/2022
2PyrazinamideFDA LinkGeneric
01/2022 - 11/2020
2Pharmaceutical PreparationsIBA
01/2022 - 01/2020
2Linezolid (Zyvox)FDA Link
01/2022 - 01/2021
1Moxifloxacin (Avelox)FDA Link
01/2022
1pretomanidIBA
01/2022
1Ethionamide (Trecator-SC)FDA Link
11/2020
1Gatifloxacin (Zymar)FDA Link
11/2020
1Ethambutol (Myambutol)FDA LinkGeneric
11/2020
1KanamycinFDA Link
06/2020
1Levofloxacin (Levaquin)FDA Link
01/2020
1Immunoglobulins (Immunoglobulin)IBA
02/2016
1EnzymesIBA
11/2011

Therapy/Procedure

5Injections
12/2021 - 01/2020
2Retreatment
04/2022 - 06/2020
1Aftercare (After-Treatment)
01/2022
1Retention in Care
01/2022
1Time-to-Treatment
11/2019
1Art Therapy
04/2014